In a phase I/II dose-escalation trial, the efficacy of a DNA vaccine encoding fusion proteins, including PSMA and a T helper cell stimulator, was evaluated in patients diagnosed with prostate cancer. The gene discussed is FOLH1; the disease is Familial prostate cancer.